163 related articles for article (PubMed ID: 35962317)
21. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
22. SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells.
Tang H; Zhao J; Zhang L; Zhao J; Zhuang Y; Liang P
Cell Mol Neurobiol; 2016 Oct; 36(7):1067-76. PubMed ID: 26643178
[TBL] [Abstract][Full Text] [Related]
23. Cytoplasmic TRADD confers a worse prognosis in glioblastoma.
Chakraborty S; Li L; Tang H; Xie Y; Puliyappadamba VT; Raisanen J; Burma S; Boothman DA; Cochran B; Wu J; Habib AA
Neoplasia; 2013 Aug; 15(8):888-97. PubMed ID: 23908590
[TBL] [Abstract][Full Text] [Related]
24. Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma.
Rajesh Y; Biswas A; Kumar U; Das S; Banerjee I; Banik P; Bharti R; Nayak S; Ghosh SK; Mandal M
Biochem Pharmacol; 2019 Jun; 164():1-16. PubMed ID: 30885764
[TBL] [Abstract][Full Text] [Related]
25. SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis.
Feng L; Zhao K; Sun L; Yin X; Zhang J; Liu C; Li B
J Transl Med; 2021 Aug; 19(1):367. PubMed ID: 34446045
[TBL] [Abstract][Full Text] [Related]
26. Graphdiyne nanoplatforms for photothermal-ferroptosis combination therapy against glioblastoma.
Zhao LX; Gong ZQ; Zhang Q; He DL; Ge RL; Meng J; Ren H; Fan YG; Wang ZY
J Control Release; 2023 Jul; 359():12-25. PubMed ID: 37244298
[TBL] [Abstract][Full Text] [Related]
27. Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
Lin R; Xu Y; Xie S; Zhang Y; Wang H; Yi GZ; Huang G; Ni B; Song H; Wang Z; Qi ST; Liu Y
J Neurooncol; 2022 Mar; 157(1):15-26. PubMed ID: 35187626
[TBL] [Abstract][Full Text] [Related]
28. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
29. A Ferroptosis-Related Prognostic Risk Score Model to Predict Clinical Significance and Immunogenic Characteristics in Glioblastoma Multiforme.
Xiao D; Zhou Y; Wang X; Zhao H; Nie C; Jiang X
Oxid Med Cell Longev; 2021; 2021():9107857. PubMed ID: 34804371
[TBL] [Abstract][Full Text] [Related]
30. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
31. Verbascoside inhibits progression of glioblastoma cells by promoting Let-7g-5p and down-regulating HMGA2 via Wnt/beta-catenin signalling blockade.
Jia WQ; Zhu JW; Yang CY; Ma J; Pu TY; Han GQ; Zou MM; Xu RX
J Cell Mol Med; 2020 Mar; 24(5):2901-2916. PubMed ID: 32000296
[TBL] [Abstract][Full Text] [Related]
32. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway.
Guan Y; He Y; Lv S; Hou X; Li L; Song J
J Drug Target; 2019 Jan; 27(1):60-66. PubMed ID: 29768063
[TBL] [Abstract][Full Text] [Related]
34. Small GTPase RHOE/RND3, a new critical regulator of NF-κB signalling in glioblastoma multiforme?
Sun Q; Dong H; Li Y; Yuan F; Xu Y; Mao S; Xiong X; Chen Q; Liu B
Cell Prolif; 2019 Sep; 52(5):e12665. PubMed ID: 31332862
[TBL] [Abstract][Full Text] [Related]
35. TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance.
Ding Z; Kloss JM; Tuncali S; Tran NL; Loftus JC
Neoplasia; 2020 Sep; 22(9):352-364. PubMed ID: 32629176
[TBL] [Abstract][Full Text] [Related]
36. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
Munoz JL; Rodriguez-Cruz V; Ramkissoon SH; Ligon KL; Greco SJ; Rameshwar P
Oncotarget; 2015 Jan; 6(2):1190-201. PubMed ID: 25595896
[TBL] [Abstract][Full Text] [Related]
37. High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistance.
Wu ZB; Cai L; Lin SJ; Xiong ZK; Lu JL; Mao Y; Yao Y; Zhou LF
Neuro Oncol; 2013 Sep; 15(9):1264-75. PubMed ID: 23828241
[TBL] [Abstract][Full Text] [Related]
38. Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma.
Cai T; Liu Y; Xiao J
Cancer Med; 2018 Apr; 7(4):1404-1415. PubMed ID: 29479863
[TBL] [Abstract][Full Text] [Related]
39. Identification of a panel of genes as a prognostic biomarker for glioblastoma.
Wang F; Zheng Z; Guan J; Qi D; Zhou S; Shen X; Wang F; Wenkert D; Kirmani B; Solouki T; Fonkem E; Wong ET; Huang JH; Wu E
EBioMedicine; 2018 Nov; 37():68-77. PubMed ID: 30341039
[TBL] [Abstract][Full Text] [Related]
40. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
